Literature DB >> 19759008

Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Valeria Faà1, Federica Incani, Alessandra Meloni, Denise Corda, Maddalena Masala, A Maria Baffico, Manuela Seia, Antonio Cao, M Cristina Rosatelli.   

Abstract

Cystic fibrosis (CF) is a common recessive disorder caused by >1600 mutations in the CF transmembrane conductance regulator (CFTR) gene. About 13% of CFTR mutations are classified as "splicing mutations," but for almost 40% of these, their role in affecting the pre-mRNA splicing of the gene is not yet defined. In this work, we describe a new splicing mutation detected in three unrelated Italian CF patients. By DNA analyses and mRNA studies, we identified the c.1002-1110_1113delTAAG mutation localized in intron 6b of the CFTR gene. At the mRNA level, this mutation creates an aberrant inclusion of a sequence of 101 nucleotides between exons 6b and 7. This sequence corresponds to a portion of intron 6b and resembles a cryptic exon because it is characterized by an upstream ag and a downstream gt sequence, which are most probably recognized as 5'- and 3'-splice sites by the spliceosome. Through functional analysis of this splicing defect, we show that this mutation abolishes the interaction of the splicing regulatory protein heterogeneous nuclear ribonucleoprotein A2/B1 with an intronic splicing regulatory element and creates a new recognition motif for the SRp75 splicing factor, causing activation of the cryptic exon. Our results show that the c.1002-1110_1113delTAAG mutation creates a new intronic splicing regulatory element in intron 6b of the CFTR gene exclusively recognized by SRp75.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759008      PMCID: PMC2781556          DOI: 10.1074/jbc.M109.032623

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Multiple splicing defects in an intronic false exon.

Authors:  H Sun; L A Chasin
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations.

Authors:  M Nissim-Rafinia; O Chiba-Falek; G Sharon; A Boss; B Kerem
Journal:  Hum Mol Genet       Date:  2000-07-22       Impact factor: 6.150

4.  Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1.

Authors:  E Ars; E Serra; J García; H Kruyer; A Gaona; C Lázaro; X Estivill
Journal:  Hum Mol Genet       Date:  2000-01-22       Impact factor: 6.150

5.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.

Authors:  M Chillón; T Casals; B Mercier; L Bassas; W Lissens; S Silber; M C Romey; J Ruiz-Romero; C Verlingue; M Claustres
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

6.  A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA-->G, produces a new exon: high frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype.

Authors:  M Chillón; T Dörk; T Casals; J Giménez; N Fonknechten; K Will; D Ramos; V Nunes; X Estivill
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

7.  Silencer elements as possible inhibitors of pseudoexon splicing.

Authors:  Manuela Sironi; Giorgia Menozzi; Laura Riva; Rachele Cagliani; Giacomo P Comi; Nereo Bresolin; Roberto Giorda; Uberto Pozzoli
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

8.  Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1.

Authors:  A Staffa; A Cochrane
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

9.  A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations.

Authors:  W E Highsmith; L H Burch; Z Zhou; J C Olsen; T E Boat; A Spock; J D Gorvoy; L Quittel; K J Friedman; L M Silverman
Journal:  N Engl J Med       Date:  1994-10-13       Impact factor: 91.245

10.  Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element.

Authors:  F Pagani; E Buratti; C Stuani; M Romano; E Zuccato; M Niksic; L Giglio; D Faraguna; F E Baralle
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

View more
  15 in total

1.  Whole-gene CFTR sequencing combined with digital RT-PCR improves genetic diagnosis of cystic fibrosis.

Authors:  Letizia Straniero; Giulia Soldà; Lucy Costantino; Manuela Seia; Paola Melotti; Carla Colombo; Rosanna Asselta; Stefano Duga
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

2.  A rare CFTR intronic mutation related to a mild CF disease in a 12-year-old girl.

Authors:  Nadia Nathan; Emmanuelle Girodon; Annick Clement; Harriet Corvol
Journal:  BMJ Case Rep       Date:  2012-11-09

Review 3.  Deep intronic mutations and human disease.

Authors:  Rita Vaz-Drago; Noélia Custódio; Maria Carmo-Fonseca
Journal:  Hum Genet       Date:  2017-05-12       Impact factor: 4.132

4.  Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSH.

Authors:  Cengiz Karakaya; Ozlem Guzeloglu-Kayisli; Rebecca J Hobbs; Tsilya Gerasimova; Asli Uyar; Mehmet Erdem; Mesut Oktem; Ahmet Erdem; Seyhan Gumuslu; Deniz Ercan; Denny Sakkas; Pierre Comizzoli; Emre Seli; Maria D Lalioti
Journal:  Mol Hum Reprod       Date:  2014-03-25       Impact factor: 4.025

5.  Identification of the second CFTR mutation in patients with congenital bilateral absence of vas deferens undergoing ART protocols.

Authors:  Rossella Giuliani; Ivana Antonucci; Isabella Torrente; Paola Grammatico; Giandomenico Palka; Liborio Stuppia
Journal:  Asian J Androl       Date:  2010-07-26       Impact factor: 3.285

6.  A synonymous mutation in the CFTR gene causes aberrant splicing in an italian patient affected by a mild form of cystic fibrosis.

Authors:  Valeria Faa'; Alessandra Coiana; Federica Incani; Lucy Costantino; Antonio Cao; Maria Cristina Rosatelli
Journal:  J Mol Diagn       Date:  2010-02-26       Impact factor: 5.568

7.  Global analysis reveals SRp20- and SRp75-specific mRNPs in cycling and neural cells.

Authors:  Minna-Liisa Ankö; Lucia Morales; Ian Henry; Andreas Beyer; Karla M Neugebauer
Journal:  Nat Struct Mol Biol       Date:  2010-07-18       Impact factor: 15.369

8.  Small-scale high-throughput sequencing-based identification of new therapeutic tools in cystic fibrosis.

Authors:  Jennifer Bonini; Jessica Varilh; Caroline Raynal; Corinne Thèze; Emmanuelle Beyne; Marie-Pierre Audrezet; Claude Ferec; Thierry Bienvenu; Emmanuelle Girodon; Sylvie Tuffery-Giraud; Marie Des Georges; Mireille Claustres; Magali Taulan-Cadars
Journal:  Genet Med       Date:  2015-01-08       Impact factor: 8.822

9.  Splice-shifting oligonucleotide (SSO) mediated blocking of an exonic splicing enhancer (ESE) created by the prevalent c.903+469T>C MTRR mutation corrects splicing and restores enzyme activity in patient cells.

Authors:  Bruno Palhais; Veronica S Præstegaard; Rugivan Sabaratnam; Thomas Koed Doktor; Seraina Lutz; Patricie Burda; Terttu Suormala; Matthias Baumgartner; Brian Fowler; Gitte Hoffmann Bruun; Henriette Skovgaard Andersen; Viktor Kožich; Brage Storstein Andresen
Journal:  Nucleic Acids Res       Date:  2015-04-15       Impact factor: 16.971

10.  Global identification of hnRNP A1 binding sites for SSO-based splicing modulation.

Authors:  Gitte H Bruun; Thomas K Doktor; Jonas Borch-Jensen; Akio Masuda; Adrian R Krainer; Kinji Ohno; Brage S Andresen
Journal:  BMC Biol       Date:  2016-07-05       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.